share_log

Vertex Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Kewalramani Reshma

Vertex Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Kewalramani Reshma

福泰製藥 | 4:持股變動聲明-高管 Kewalramani Reshma
美股SEC公告 ·  08/01 16:23
Moomoo AI 已提取核心訊息
Vertex Pharmaceuticals CEO & President, Kewalramani Reshma, completed a sale of 15,202 shares of common stock on July 30, 2024. The transaction was executed at a price of $505.00 per share, resulting in a total market value of $7,677,010. Following the sale, Reshma's direct holdings in the company amount to 90,970 shares. The sale took place through an open market or private sale, as indicated by the transaction code 'S'.
Vertex Pharmaceuticals CEO & President, Kewalramani Reshma, completed a sale of 15,202 shares of common stock on July 30, 2024. The transaction was executed at a price of $505.00 per share, resulting in a total market value of $7,677,010. Following the sale, Reshma's direct holdings in the company amount to 90,970 shares. The sale took place through an open market or private sale, as indicated by the transaction code 'S'.
福泰製藥首席執行官兼總裁Kewalramani Reshma於2024年7月30日完成了15202股普通股的出售。該交易價格爲每股505.00美元,總市值爲7,677,010美元。出售後,Reshma在公司內的直接持股數量爲90,970股。該銷售通過公開市場或私人交易進行,由交易代碼“S”表示。
福泰製藥首席執行官兼總裁Kewalramani Reshma於2024年7月30日完成了15202股普通股的出售。該交易價格爲每股505.00美元,總市值爲7,677,010美元。出售後,Reshma在公司內的直接持股數量爲90,970股。該銷售通過公開市場或私人交易進行,由交易代碼“S”表示。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息